GT Biopharma (GTBP) Expected to Announce Earnings on Friday

GT Biopharma (NASDAQ:GTBP) is expected to be announcing its Q4 2025 results before the market opens on Friday, February 20th. Analysts expect GT Biopharma to post earnings of ($0.22) per share for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, March 13, 2026 at 4:00 PM ET.

GT Biopharma Stock Performance

Shares of NASDAQ:GTBP opened at $0.46 on Wednesday. The stock’s 50-day moving average is $0.68 and its 200-day moving average is $0.81. The company has a market cap of $4.86 million, a P/E ratio of -0.14 and a beta of 1.21. GT Biopharma has a 52-week low of $0.40 and a 52-week high of $3.85.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e)” rating on shares of GT Biopharma in a report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.

GT Biopharma Company Profile

GT Biopharma, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events.

The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS).